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Summary
Background Dupilumab is the first biologic registered for the treatment of moder-
ate-to-severe atopic dermatitis (AD), and efficacy was shown in phase III clinical
trials (primary outcome at week 16 was reached in 38% of patients). Currently,
there are limited daily practice data available for dupilumab, especially when it is
combined with systemic immunosuppressants.
Objectives To evaluate dupilumab treatment in daily practice in patients with AD.
Methods In this observational cohort study, we prospectively included all adult
patients with AD who had been treated with dupilumab in two university hospi-
tals in the Netherlands. Concomitant systemic immunosuppressive treatment was
monitored. Physician-reported outcome measures and patient-reported outcome
measures (PROMs) after ≥ 12 weeks of follow-up were analysed. We used a lin-
ear mixed-effects model to determine changes in scores during follow-up.
Results Ninety-five patients were included. Of these, 62 patients were using sys-
temic immunosuppressants at baseline; the use of systemic immunosuppressants
was continued during dupilumab treatment in 43 patients. From baseline to 16
weeks of treatment, the estimated mean Eczema Area and Severity Index score
(0–72) decreased from 186 [95% confidence interval (CI) 160–214)] to 73
(95% CI 54–100), and the estimated mean PROMs showed a decrease of 41–
66%. Investigator’s Global Assessment 0 or 1 (clear/almost clear) was reached in
38% of the patients. Five patients discontinued dupilumab treatment due to side-
effects or ineffectiveness. Eye symptoms and orofacial (nonocular) herpes simplex
virus (HSV) reactivation were reported in 62% and 8% of the patients, respec-
tively.
Conclusions Dupilumab treatment in daily practice shows a clinically relevant
improvement of physician-reported outcome measures and PROMs, which is in
line with efficacy data from clinical trials. Besides frequently reported eye symp-
toms and orofacial (nonocular) HSV reactivation, there were no apparent safety
concerns.
What’s already known about this topic?
• Dupilumab has been shown to be an efficacious treatment for atopic dermatitis in
several clinical trials.
• However, it is known that there may be considerable differences in patient charac-
teristics and treatment responses between clinical trials and daily practice.
What does this study add?
• This study presents the first experience with dupilumab treatment in 95 patients
with atopic dermatitis in daily practice in two Dutch university hospitals.
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• Less stringent inclusion and exclusion criteria and follow-up schedules, in contrast
to those used in clinical trials, might better represent daily practice.
• Dupilumab treatment shows a clinically relevant improvement of physician- and
patient-reported outcome measures; besides patient-reported eye symptoms (in 59
of 95 patients; 62%) and an apparent increase in orofacial (nonocular) herpes sim-
plex virus reactivation (eight of 95 patients; 8%), there were no other safety con-
cerns during follow-up up to 16 weeks of dupilumab treatment.
Atopic dermatitis (AD) is a complex and heterogeneous
chronic inflammatory skin disease. AD is characterized by sev-
ere itch and recurrent eczematous lesions. Up to 20% of the
worldwide paediatric population and approximately 2–10% of
all adults have AD.1,2 AD can have a profound negative effect
on quality of life as it is the skin disease with the highest non-
fatal health burden.1
In addition to being advised to avoid triggers and use mois-
turizers, patients with AD are mostly treated with topical corti-
costeroids (TCSs) and topical calcineurin inhibitors (TCIs).
Around 15% of patients with AD are considered to have mod-
erate-to-severe disease requiring phototherapy or systemic
immunosuppressive therapy.3,4 The use of systemic glucocorti-
costeroids, phototherapy and conventional systemic immuno-
suppressive agents, including ciclosporin A, azathioprine,
mycophenolic acid, mycophenolate mofetil and methotrexate,
can be effective and is well tolerated in many patients but
may have limitations such as side-effects and an unfavourable
risk–benefit ratio.5–7 In addition, most of these treatments are
used off-label and there are limited long-term treatment data
available.5,8–10
Dupilumab, the first biologic for the treatment of moder-
ate-to-severe AD, is a fully human IgG4 monoclonal antibody
that targets the interleukin (IL)-4 receptor a chain, inhibiting
the effects of cytokines IL-4 and IL-13.11 These cytokines are
thought to play a central role in the pathogenesis of AD. Dupi-
lumab has been approved recently, after it was shown to be a
successful treatment for AD in several phase III clinical tri-
als.11–13 These trials showed improvement of disease severity,
itch, sleep disturbance, anxiety, depression and quality of life
with dupilumab as monotherapy or in combination with
TCSs.3 The most frequently observed side-effects were con-
junctivitis, herpes infections and injection-site reactions.3,11
However, there may be considerable differences in patient
characteristics and treatment responses between clinical trials
and daily practice (i.e. efficacy vs. effectiveness). This is partly
explained by strict inclusion and exclusion criteria, treatment
adherence and prohibited medication and procedures in clinical
trials, which may limit the ability to answer questions related to
daily practice.14 Observational studies in a real-world setting are
therefore essential to document the benefits and harms of a ther-
apy in a wider patient population. Here, we present and evaluate
daily practice data for dupilumab treatment combined with the
use of systemic immunosuppressants in patients with AD.
Patients and methods
Study design and patients
This prospective multicentre observational longitudinal cohort
study consecutively included all patients with AD who had a
history of systemic immunosuppressive treatment and had
started dupilumab treatment in the context of standard care
from October 2017 to September 2018 at the Erasmus Univer-
sity Medical Center (Rotterdam, the Netherlands) or the Ams-
terdam University Medical Center (Amsterdam, the
Netherlands). There was only one patient who refrained from
participation.
All patients were aged ≥ 18 years and fulfilled the criteria
for dupilumab treatment set forth by the Dutch Society of
Dermatology and Venereology (Appendix S1; see Supporting
Information).15 Patients visited the outpatient clinic at base-
line, week 4 and after either 12 (Amsterdam University Medi-
cal Center) or 16 (Erasmus University Medical Center) weeks
of treatment. In one of the centres, data were collected
according to the harmonized dataset of the TREAT Registry
Taskforce.16–18
Treatment
A 600-mg loading dose of dupilumab was injected subcuta-
neously at baseline, followed by an injection of 300 mg dupi-
lumab every other week.19 Patients either discontinued
systemic immunosuppressive treatment before starting dupilu-
mab treatment or continued the immunosuppressant during
dupilumab treatment, on the basis of a shared decision. The
(dis)continuation or initiation of systemic immunosuppres-
sants during dupilumab treatment was recorded and moni-
tored. During dupilumab treatment, patients were encouraged
to continue the use of moisturizers, TCSs and TCIs, which
were not monitored specifically.
Outcome measures
Patient characteristics and previous and current AD treatment
were assessed at baseline. Clinical examinations were con-
ducted by a maximum of seven trained and proficient raters at
each visit. Physician-reported severity was reported using the
Eczema Area and Severity Index (EASI; 0–72) and the
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Investigator’s Global Assessment for AD (IGA; 0–4).20,21 In
addition, patient-reported outcome measures (PROMs) were
assessed at every visit; these included a numeric rating scale
(NRS) to assess pruritus for the 7 days or 24 h prior to the
visit (referred to hereafter as NRS peak pruritus past 7 days
and NRS peak pruritus past 24 h, respectively; 0–10),22 the
Dermatology Life Quality Index (DLQI; 0–30) and the Patient-
Oriented Eczema Measure (POEM; 0–28).23,24 These outcome
measures are in line with the core outcome set defined by the
global Harmonising Outcome Measures for Eczema (HOME)
initiative.25,26 Furthermore, we calculated the number of days
until the minimal clinically important difference (MCID) was
reached, as well as the proportion of patients who reached the
MCID at follow-up (12–16 weeks).27,28 Patients with a base-
line score lower than the MCID were excluded from this anal-
ysis. Collection of blood samples (liver, renal and
haematological tests) and additional safety assessments (i.e.
blood pressure measurement and urinalysis) in patients with
concomitant use of systemic immunosuppressants were con-
ducted to monitor safety. Furthermore, potential drug-related
adverse events were recorded.
Evaluation of effectiveness
Treatment effect was evaluated using the estimated mean
change in EASI scores over time in the first 16 weeks of dupi-
lumab treatment, and IGA scores recorded at baseline and fol-
low-up (12–16 weeks). Furthermore, the estimated mean
changes in PROMs (NRS peak pruritus past 7 days/24 h,
POEM and DLQI) over time in the first 16 weeks of treatment
were analysed. These estimated mean scores were based on
our linear mixed-effects (LME) model.
Data analysis
Studying data on patients treated in a real-world setting comes
with several challenges, due to variation resulting from the use
of inclusion and exclusion criteria and follow-up schedules that
are less stringent than those used in clinical trials. To evaluate
the effectiveness of dupilumab, we used LME models to describe
and present changes in the repeatedly measured, continuous
scores of interest in time (days since start of treatment). The use
of these models allows for the analysis of unbalanced repeated
measurements, that is, measurements that are not taken at
exactly the same points in time for all patients. The use of this
model is more efficient than cross-sectional analyses that only
consider a subset of measurements taken at a particular point in
time. The use of random effects makes it possible to take into
account the fact that measurements originating from the same
patients are not independent. We analysed measurements per-
formed at visits from the start up to and including 17 weeks (16
weeks, visit window of +7 days) of treatment. The use of
square-root transformations to normalize the residuals and
improve the model fit was confirmed by evaluating histograms
of the data and using the Akaike Information Criterion
(Appendix S2; see Supporting Information).
Predicted values of the (continuous) score of interest,
which are shown in the figures, are based on the LME models
and transformed back to the original scale. Confidence inter-
vals (CIs) for the predicted values were determined using the
bootstrap method. We used natural cubic splines to model the
nonlinear association between outcomes and follow-up time.
This nonlinear association was confirmed and the appropriate
number of degrees of freedom was chosen based on the
Akaike Information Criterion.29,30 Visual evaluation of the tra-
jectories estimated by the spline showed that they could not
be approximated by a piecewise linear fit, which would have
the advantage of directly interpretable parameter estimates.
Sex, age and concomitant immunosuppressive treatment were
included as covariates in our model. We allowed the estimated
trajectories over time to differ between treatment groups by
including interaction terms. However, as the likelihood ratio
test showed that there was no evidence for these interactions,
we did not include them in the final model, in the interest of
the interpretability of the parameter.
Analyses were performed using SPSS 240 (IBM, Armonk,
NY, U.S.A.) and R version 341 (R Foundation for Statistical
Computing, Vienna, Austria).
Ethical approval
Our study was exempted from evaluation by the local medical
research ethics committees (MEC-2017-1123; W18_
097#18123). The study conduct was in accordance with the
STROBE recommendations.31
Results
Population
Table 1 presents the baseline characteristics of the 95 patients
(Erasmus University Medical Center: n = 60; Amsterdam
University Medical Center: n = 35) included in our analyses.
Sixty-two per cent (59 of 95) of the patients were male,
with a median age of 42 years (interquartile range 27–52
years). Onset of AD was before the age of 2 years in 72%
(68 of 95) of the patients. Asthma (65%), allergic contact
dermatitis (45%), and allergic (rhino)conjunctivitis and/or
atopic (kerato)conjunctivitis (72%) were reported. All of the
patients had been treated with systemic immunosuppressants
prior to the start of dupilumab treatment, and 72% had used
at least two different conventional systemic immunosuppres-
sants, mostly ciclosporin A (88%) and methotrexate (58%)
(Table 1).
The median IGA score at baseline was 30 (interquartile
range 20–30). Based on the LME model, at baseline, patients
had an estimated mean EASI score of 186 (95% CI 160–
214), an estimated mean POEM score of 214 (95% CI 197–
233), an estimated mean score for NRS peak pruritus past 7
days of 74 (95% CI 61–86), an estimated mean score for
NRS peak pruritus past 24 h of 75 (95% CI 61–89) and an
estimated mean DLQI score of 125 (95% CI 104–146).
© 2019 The Authors. British Journal of Dermatology
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Effectiveness of dupilumab treatment
Figure 1 shows the changes in the outcome measures over time,
up to 12 weeks (NRS peak pruritus past 24 h) and 16 weeks
(EASI, POEM, NRS peak pruritus past 7 days) of treatment. The
IGA scores, measured at baseline and follow-up, and the change
in the estimated mean DLQI scores are shown in Figures S1 and
S2 (see Supporting Information). The estimated mean EASI
scores and PROMs at baseline and after 12 or 16 weeks of treat-
ment, based on our LME model, are shown in Table 2. The per-
centage change from baseline to 16 weeks of treatment was
61% (95% CI 71%, 46%) for EASI, 53% (95% CI 63%,
44%) for POEM and 41% (95% CI 53%, 30%) for NRS
peak pruritus past 7 days; the percentage change for NRS peak
pruritus past 24 h from baseline to 12 weeks of treatment was
57% (95% CI 99%, 23%). IGA 0 or 1 (clear or almost
clear) was reached in 38% of the patients. Table 3 shows that
the MCID for all outcome measures is estimated to be reached
within 5 weeks of treatment. At 12–16 weeks of follow-up, the
MCIDs for EASI, POEM, DLQI, the NRS peak pruritus past 7 days
and the NRS peak pruritus past 24 h were reached in 66%, 86%,
65%, 65% and 70% of the patients, respectively.27,28
In our cohort, 62 patients (65%) were using systemic
immunosuppressants, including systemic glucocorticosteroids,
at the start of dupilumab treatment. Systemic immunosuppres-
sive treatment was continued during dupilumab treatment in
43 patients (43 of 95, 45%; Table 4). Table 4 shows that
concomitant immunosuppressants were successfully tapered
off and stopped in 34 patients (29 of 43, 67%) in the first 16
weeks of treatment. In five patients with flares or insufficient
response to dupilumab treatment, systemic glucocorticos-
teroids were started for a period of 2–8 weeks. Three patients
were treated with systemic antibiotics.
Side-effects
In our cohort, 59 patients (59 of 95, 62%) reported eye
symptoms, including redness, itching, stinging, burning, tear-
ing, scaling, crusting and foreign body sensation. Sixteen
patients consulted an ophthalmologist; of these, 13 patients
were diagnosed with (allergic) (kerato)conjunctivitis (n = 9),
blepharitis (n = 2) or sicca (n = 2). Most patients were treated
with artificial tears, antihistamine eyedrops, fluorometholone
01% eyedrops or tacrolimus 003% eye ointment. The preva-
lence of pre-existing ocular comorbidities in our cohort is
unknown. In addition, 12 episodes of orofacial herpes simplex
virus (HSV) reactivation were reported in eight patients (eight
of 95, 8%), with recurrent infections during follow-up in
three patients (Table S1; see Supporting Information). None
of these patients had HSV infections around the eyes. In addi-
tion, none of these patients experienced eye pain, chemosis or
blurred vision, which makes the possibility of their having
HSV eye infections highly unlikely.32 There were no clinically
significant changes in laboratory parameters or additional
safety assessments (i.e. blood pressure measurement and uri-
nalysis) in those patients with concomitant use of systemic
immunosuppressants.
Discontinuation of dupilumab treatment
Five patients discontinued dupilumab treatment. One of these
discontinued dupilumab treatment because of a monoarthritis
Table 1 Demographic and clinical characteristics of the patients at
baseline (n = 95)a
Characteristic
Age at the start of dupilumab
treatment (years), median (IQR)
42 (27–52)
Male, n (%) 59 (62)
Race, n (%)
White 73 (77)
Black 9 (9)
Asian 11 (12)
Otherb 2 (2)
Age of onset, n (%)
0 to < 2 years 68 (72)
2 to < 6 years 11 (12)
6 to < 18 years 8 (8)
≥ 18 years 7 (7)
Age of onset (years), median (IQR) 0 (00–20)c
Disease duration until start of dupilumab
(years), mean  SD
355  165c
Previous use of conventional systemic
immunosuppressants, n (%)e,f
Ciclosporin A 84 (88)
Methotrexate 55 (58)
Azathioprine 29 (31)
Mycophenolic acid/mycophenolate mofetil 36 (38)
Number of previous used conventional systemic
immunosuppressants, n (%)e
1 27 (28)
2 36 (38)
3 23 (24)
4 9 (9)
Atopic/allergic conditions, n (%)g
Asthma 62 (65)
Allergic (rhino)conjunctivitis/atopic
(kerato)conjuncitvitish
68 (72)
Allergic contact dermatitisi 43 (45)
Body mass index, median (IQR) 250 (223–283)d
IQR, interquartile range. aDiagnosis of atopic dermatitis based on
the U.K. Working Party’s Diagnostic Criteria for Atopic Dermati-
tis: n = 35; bChinese-Creole (n = 1), Dutch-Indonesian (n = 1);
cmissing data: n = 1 (1%); dmissing data: n = 3 (3%); eprevious
use of systemic glucocorticoids is not reported because of
anamnestic inconsistency in short- and long-term use; fbesides
conventional systemic immunosuppressants, the following sys-
temic therapies were used: dupilumab, study (n = 2); apremilast
(n = 2); ustekinumab (n = 1); omalizumab (n = 1); alitretinoin
(n = 2); lebrikizumab, study (n = 2); fevipiprant, study (n = 1);
and upadacitinib, study (n = 1); gpatient reported (n = 60),
physician diagnosed (n = 30); hmerged as one category because
of the differences in definition and registration in the two uni-
versity hospitals; ipositive patch tests in history; the other 55% is
‘tested negative’, ‘never tested’ or ‘unknown’.
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in the right ankle, which started a few days after the first
dupilumab administration. The other four patients discontin-
ued because of a lack of clinical response after 9, 15, 17 and
18 weeks, respectively. No evident common phenotypical
characteristics, laboratory markers or other predictors of fail-
ure could be detected in these patients.
Discussion
In this observational study, dupilumab treatment was evalu-
ated in a daily practice cohort of 95 patients who had AD
and whose eczema could not be adequately controlled with
TCSs, TCIs or conventional systemic immunosuppressants.
Dupilumab treatment resulted in a rapid decrease in EASI,
IGA, POEM, DLQI and NRS peak pruritus past 7 days/24 h
scores in the first 16 weeks of treatment (Fig. 1 and Table 2;
see also Fig. S1, Fig. S2 and Table S2; see Supporting Infor-
mation). Overall, dupilumab was well tolerated in most
patients, although 62% of the patients reported eye symp-
toms (Table S1; see Supporting Information). In contrast to
the case in previous clinical trials and the limited daily prac-
tice literature, in this study, dupilumab treatment was com-
bined with concomitant systemic immunosuppressants in
45% (43 of 95) of the patients.11,33 Continuation of conven-
tional systemic immunosuppressants in the first weeks of
dupilumab treatment seems to be an effective and safe way
to transition to monotherapy with dupilumab but this needs
to be studied in larger numbers of patients. This emphasizes
the importance of the introduction of registries such as the
national registries of the TREatment of ATopic eczema
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Fig 1. Estimated mean change in Eczema Area and Severity Index
(EASI), Patient-Oriented Eczema Measure (POEM) and numeric rating
scale (NRS) scores for peak pruritus for the past 7 days or 24 h (NRS
peak pruritus past 7 days and NRS peak pruritus past 24 h,
respectively) in patients with atopic dermatitis (n = 95). A linear
mixed-effects model was used to model changes over time. Higher
scores indicate a worsened state. The grey area represents the 95%
confidence interval (CI). (a) The estimated mean EASI score (0–72)
decreased from 186 (95% CI 160–214) at baseline to 73 (95% CI
54–100) at 16 weeks of dupilumab treatment. An outlier presenting
with an EASI score of 72 at baseline is not shown in this figure but is
included in the model. (b) The estimated mean POEM score (0–28)
decreased from 214 (95% CI 197–233) at baseline to 101 (95% CI
79–122) at 16 weeks of dupilumab treatment. (c, d) Pruritus was
evaluated differently in the two university hospitals: the Erasmus
University Medical Center used the NRS peak pruritus score for the 7
days prior to the visit, while the Amsterdam University Medical
Center used the NRS peak pruritus score for the 24 h prior to the
visit. (c) The estimated mean NRS peak pruritus past 7 days score (0–
10) decreased from 74 (95% CI 62–86) at baseline to 44 (95% CI
36–55) at 16 weeks of treatment; these data are derived from the
observation of 60 patients during 16 weeks of follow-up. (d) The
estimated mean NRS peak pruritus past 24 h score (0–10) decreased
from 75 (95% CI 61–89) at baseline to 32 (95% CI 22–43) at 12
weeks of treatment; these data are derived from the observation of 35
patients during 12 weeks of follow-up.
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(TREAT) Registry Taskforce for monitoring systemic treat-
ments in daily practice.18
Although the methodology and follow-up visits used in our
study, clinical trials and the limited daily practice literature
available were different, we tried to compare results.11,33–37
Overall, patients in the current study had lower baseline
EASI scores than patients in previous dupilumab studies and
trials (Table S2; see Supporting Information).11 In our study,
patients were not asked to discontinue topical steroids or sys-
temic immunosuppressants before the start of dupilumab
treatment, resulting in lower baseline EASI scores than those
from clinical trials that required a minimum washout period
of 2 and 4 weeks, respectively. Currently available daily prac-
tice studies with relatively high EASI scores did not report the
presence of systemic treatment at baseline.34,35 From clinical
experience, we know that discontinuation of systemic
immunosuppressants in patients with AD often results in the
exacerbation of their disease.38 Therefore, the use of conven-
tional systemic immunosuppressants during dupilumab treat-
ment was continued initially in a subset of patients, in a
tapering schedule guided by PROMs. Although it would be
interesting to study whether using dupilumab together with
one of the systemic immunosuppressants used in our patient
population would be of particular benefit, we did not perform
inter- and intragroup comparisons between patients on differ-
ent concomitant systemic immunosuppressants because this
would have led to nonrobust conclusions, due to the relatively
small subsets of patients (Table 4).
Interestingly, baseline PROMs in daily practice, including
NRS peak pruritus past 7 days/24 h, POEM and DLQI, were
comparable with those from patients’ clinical trials (Table S2;
see Supporting Information).11 Even though 65% (62 of 95)
of patients in this study were still being treated with a systemic
immunosuppressant at baseline, they had relatively poor
PROMs at the start of dupilumab treatment. This might be the
result of a long history of severe disease in most patients in
our cohort, in contrast to the case with patients in previous
clinical trials. Although Dutch regulations do not require
patients to have a minimum severity score to warrant dupilu-
mab treatment, they do require patients to have failed treat-
ment with at least one systemic immunosuppressant in a
sufficient dose for at least 4 months with intensive guidance
and instructions (Appendix S1; see Supporting Information).
The majority of patients in our study (72%), and a similar pro-
portion of patients in the daily practice studies available, had
been treated with at least two different conventional systemic
Table 2 Effectiveness of dupilumab in daily practice
Outcome measure (range)
Estimated mean
score at baseline
(95% CI)
Estimated mean score
at the end of
follow-up (95% CI)
Change in score
from baseline to the end
of follow-up (%) (95% CI)
EASI (0–72) 186 (160–214) 73 (54–100) 61 (71, 46)
POEM (0–28) 214 (197–233) 101 (79–122) 53 (63, 44)
NRS peak pruritus past 7 days (0–10)a 74 (62–86) 44 (36–55) 41 (53, 30)
NRS peak pruritus past 24 h (0–10)b 75 (61–89) 32 (22–43) 57 (99, 23)
DLQI (0–30) 125 (105–145) 43 (28–59) 66 (75, 47)
EASI, Eczema Area and Severity Index; CI, confidence interval; POEM, Patient-Oriented Eczema Measure; NRS, numeric rating scale; DLQI,
Dermatology Life Quality Index; the estimated mean scores in our cohort were derived via the use of a linear mixed-effects model; confi-
dence intervals for the predicted values were determined using the bootstrap method; the percentage change in our cohort was based on the
estimated mean baseline score and the estimated mean score at 16 weeks of treatment; adata derived from the observation of 60 patients dur-
ing 16 weeks of follow-up; bdata derived from the observation of 35 patients during 12 weeks of follow-up.
Table 3 Minimal clinically important differences (MCIDs)
EASI POEM DLQI
NRS peak
pruritus
past 7 daysa
NRS peak
pruritus
past 24 hb
MCID 66 34 4 27 27
Time until MCID is reached (days)c 29 9 11 29 21
Percentage of patients reaching MCID after
12–16 weeks of treatment (%)
66 86 65 65 70
Number of patients with a baseline score < MCIDd 20 0 7 2 1
EASI, Eczema Area and Severity Index; POEM, Patient-Oriented Eczema Measure; DLQI, Dermatology Life Quality Index; NRS, numeric rating
scale; adata derived from the observation of 60 patients during 16 weeks of follow-up; bdata derived from the observation of 35 patients
during 12 weeks of follow-up; cestimation derived using a linear mixed-effects model; dpatients with a baseline score < MCID were excluded
from the MCID analyses.
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immunosuppressants, in contrast to a minority (26–28%) who
used at least one systemic immunosuppressant in the SOLO tri-
als.11,33–37 This suggests that patients in daily practice are at
the end of the ‘severity spectrum’. Because a long-term severity
measure is not available, surrogate markers such as previous
treatment with systemic immunosuppressants may be used.
Interestingly, a comparable relative reduction in both physi-
cian-reported severity and PROMs is achieved after at least 12
weeks of treatment (Figure 1 and Table 2; also see Figure S1
and Table S2; see Supporting Information), although direct
comparison of these scores is complicated due to the different
study designs used in this study, other daily practice studies
and SOLO trials.11,33–37 The percentage of patients reaching
IGA 0/1 in our patient population (38%) is equal to the per-
centage of patients reaching the primary end point in the
SOLO1/2 trials (38%; Fig. S2; see Supporting Information).
However, in addition to IGA 0/1, an improvement of ≥ 2 on
IGA was required in the SOLO trials.
We observed that the MCIDs for the PROMs (POEM, DLQI,
NRS peak pruritus past 7 days/24 h) were reached prior to
that for the physician-reported severity score (EASI), which
suggests that patients’ symptoms improve prior to clinical
severity. This corresponds to our clinical observation that, in
dupilumab-treated patients, the itch improves before the
eczema disappears.
In our cohort, 62% (59 of 95) of the patients presented
with eye symptoms suggestive for conjunctivitis, sicca and/or
blepharitis, whereas conjunctivitis was observed in only 4–5%
of the patients in the SOLO trials.11 However, the limited
daily practice literature available also showed conjunctivitis
incidence ranges up to 50% in patients treated with
dupilumab.33–37 Literature on ocular comorbidities in AD
shows that several ocular comorbidities are more prevalent
among patients with AD than among the general population.39
Additionally, Thyssen et al. recently showed that this increased
risk and prevalence is disease-severity dependent.40,41 We
hypothesize that the difference between real-world and clinical
trials may be explained by differences in (long-term) disease
severity in patients in this study, as discussed above. In addi-
tion, a reporting bias may have been induced by specifically
asking about eye complaints.
We found an incidence of 8% (eight of 95) of orofacial
HSV reactivation in our cohort. The absence of typical HSV-
infection-related eye complaints makes HSV eye involvement
in these infections highly unlikely. A recent meta-analysis
showed a slightly lower incidence of 61% reported in dupilu-
mab clinical trials.42 This incidence was not significantly dif-
ferent in patients in the placebo groups (52%). Possibly,
concomitant systemic immunosuppressants, which were used
in four of eight patients, may have contributed to the higher
incidence found in our cohort. Moreover, in the previously
mentioned clinical trials, it was found that there was a higher
incidence of severe and clinically important herpes infections,
including herpes zoster and eczema herpeticum, in the pla-
cebo groups.43 In our cohort, there were no cases of severe,
clinically important herpes infections.
Daily practice data were prospectively collected at two uni-
versity medical hospitals in the Netherlands. Although the cen-
tres used slightly different follow-up schedules (12 weeks vs.
16 weeks), different outcome measures (NRS peak pruritus
past 24 h vs. NRS peak pruritus past 7 days) and different
assessments of baseline characteristics (allergic comorbidities
vs. the U.K. Workings Party’s Diagnostic Criteria for Atopic
Dermatitis), we were able to analyse the data by using an LME
model. However, as a result, we could not retrieve a standard
deviation for the outcomes as advised by the reporting guide-
lines for clinical trials of the HOME initiative.44
Table 4 Concomitant systemic immunosuppressive treatment in
patients undergoing dupilumab treatment (total n = 95)
Category Patients (%)
Discontinued systemic immunosuppressive
treatment prior to or at the start
of dupilumab treatmenta
52 (55)
Discontinued systemic immunosuppressive
treatment in the first 16 weeks of
dupilumab treatmentb
29 (31)
Discontinued CsA 8 (8)
Discontinued AZA 3 (3)
Discontinued MTX 1 (1)
Discontinued MPA/MMF 2 (2)
Discontinued prednisone 15 (16)
Underwent systemic immunosuppressive
treatment for > 16 weeks of
dupilumab treatment
9 (9)
Treated with CsA 3 (3)
Treated with AZA 0 (0)
Treated with MTX 1 (1)
Treated with MPA/MMF 2 (2)
Treated with prednisone 3 (3)
Treated with multiple systemic
immunosuppressantsc
5 (5)
CsA, ciclosporin A; AZA, azathioprine; MTX, methotrexate; MPA,
mycophenolic acid; MMF, mycophenolate mofetil; anineteen of
the patients in this group (19 of 95; 20%) discontinued systemic
immunosuppressive treatment at the start of or one day before
starting dupilumab treatment; of these, four patients (four of 95;
4%) were being treated with CsA, three patients (three of 95;
3%) were being treated with AZA, 11 patients (11 of 95; 12%)
were being treated with MTX, and one (one of 95; 1%) was
being treated with prednisone; bmedian number of weeks sys-
temic immunosuppressive treatments was continued: CsA, 6
weeks; AZA, 7 weeks; MTX, 4 weeks; MPA/MMF, 10 weeks;
prednisone, 4 weeks; cin one patient, prednisone was continued
for 4 weeks but MPA was discontinued at the start of dupilumab
treatment; in one patient, AZA was continued for 4 weeks and
prednisone was continued for 16 weeks; in one patient, pred-
nisone was continued for 16 weeks but apremilast was discon-
tinued at start of dupilumab treatment; in one patient, AZA was
continued for 7 weeks but prednisone was discontinued at the
start of dupilumab treatment; and, in one patient, MPA was con-
tinued for 16 weeks but CsA was discontinued at the start of
dupilumab treatment.
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In addition to acquiring short-term follow-up data, con-
tinuous collection of real-world and standardized data is
important in order to evaluate the effectiveness and safety
of dupilumab treatment in daily practice in the long term.
The TREAT Registry Taskforce (http://treat-registry-taskf
orce.org/) is an international network of national registries
that aim to collect such data.18 Such registries intend to
gather observational real-world data of paediatric and adult
patients with AD and receiving phototherapy and systemic
therapy, using a harmonized dataset including time
points.16,17 The TREAT NL registry is the Dutch TREAT
registry, and data from this registry were used for the cur-
rent study.
In conclusion, in our daily practice cohort, we confirmed
that dupilumab is an effective treatment in the vast majority
of patients with moderate-to-severe AD. Furthermore, we
report on the concomitant use of conventional systemic
immunosuppressive agents in a subset of patients. In the
patients reported in this study, we found a high reporting rate
of eye symptoms, and an apparent increase in orofacial
(nonocular) HSV reactivation. No other safety concerns were
reported in the first 16 weeks of dupilumab treatment.
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